Castle Biosciences, Inc. (CSTL)

NGM – Real vaqt narxi. Valyuta: USD

18.63

-0.41 (-2.15%)

Yopilishda: May 12, 2026, 4:00 PM EDT

18.73

+0.10 (0.52%)

Bozor oldidan: May 13, 2026, 4:07 AM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Castle Biosciences, Inc. (CSTL)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Castle Biosciences, Inc. (CSTL)

Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference

Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation

Castle Biosciences, Inc. (CSTL) Q1 2026 Earnings Call Transcript

Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Beats Revenue Estimates

Castle Biosciences Reports First Quarter 2026 Results

Wall Street Analysts Predict an 85.15% Upside in Castle Biosciences (CSTL): Here's What You Should Know

Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month

Videolar

No Data

Press-relizlar

Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation

Castle Biosciences Reports First Quarter 2026 Results

Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month

New Data at DDW 2026 Show TissueCypher® Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barrett's Esophagus

Search stocks

Castle Biosciences, Inc. (CSTL)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Castle Biosciences, Inc. (CSTL)

Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference

Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation

Castle Biosciences, Inc. (CSTL) Q1 2026 Earnings Call Transcript

Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Beats Revenue Estimates

Castle Biosciences Reports First Quarter 2026 Results

Wall Street Analysts Predict an 85.15% Upside in Castle Biosciences (CSTL): Here's What You Should Know

Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month

Videolar

No Data

Press-relizlar

Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation

Castle Biosciences Reports First Quarter 2026 Results

Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month

New Data at DDW 2026 Show TissueCypher® Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barrett's Esophagus